G207
Description
Name: G207
Type: biotech
Groups: investigational
Indication: Investigated for use/treatment in brain cancer.
Accession Number: DB05827 ( DB05827)
Description: G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG. These viruses are specific herpes simplex viruses, or HSVs, generally known as the cause of cold sores. MediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable as a therapeutic agent in humans.
Structure:
Prescription Products: Not Available
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
Brand Names
Brand Mixtures
Categories
Type: biotech
Groups: investigational
Indication: Investigated for use/treatment in brain cancer.
Accession Number: DB05827 ( DB05827)
Description: G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG. These viruses are specific herpes simplex viruses, or HSVs, generally known as the cause of cold sores. MediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable as a therapeutic agent in humans.
Structure:
Prescription Products: Not Available
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
| Brand Name | Ingredients |
|---|
| Brand Name | Ingredients |
|---|
Categories
- No Category
Pharmacology
Indication: Investigated for use/treatment in brain cancer.
Pharmacodynamics: Not Available
Mechanism of action: G207, Cancer killing viruses are modified to make them utilizable as a therapeutic agent in human by switching off certain genes that normally enable the virus to multiply in healthy cells, which would destroy these cells. As a result of this genetic modification, the HSVs are able to reproduce in tumor cells solely, since only this offer an environment that compensates for the loss of the removed viral genes. Consequently, the virus is able to replicate in the tumor cells, selectively destroying them without harming healthy tissue.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Not Available
Affected organisms
SNP Mediated Adverse Drug Reactions
Pharmacodynamics: Not Available
Mechanism of action: G207, Cancer killing viruses are modified to make them utilizable as a therapeutic agent in human by switching off certain genes that normally enable the virus to multiply in healthy cells, which would destroy these cells. As a result of this genetic modification, the HSVs are able to reproduce in tumor cells solely, since only this offer an environment that compensates for the loss of the removed viral genes. Consequently, the virus is able to replicate in the tumor cells, selectively destroying them without harming healthy tissue.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Not Available
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
Manufacturers:
Packagers:
Dosage forms
Prices
Patents
- Not Available
Packagers:
- Not Available
Dosage forms
| Form | Route | Strength |
|---|
| Form | Route | Strength |
|---|
Prices
| Unit description | Cost | Unit |
|---|
| Unit description | Cost | Unit |
|---|
Patents
| Country | Patent Number | Approved | Expires (estimated) |
|---|
Interactions
Drug Interactions
Food Interactions:
| Drug | Interaction |
|---|
| Drug | Interaction |
|---|
Food Interactions:
- Not Available
Taxonomy
Kingdom: Organic Compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
substituent:
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- Not Available
substituent:
- Not Available
References
Synthesis Reference: Not Available
General Reference: # Todo T: Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci. 2008 Jan 1;13:2060-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17981691 # Radbill AE, Reddy AT, Markert JM, Wyss JM, Pike MM, Akella NS, Bharara N, Gillespie GY: Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain. J Neurovirol. 2007 Apr;13(2):118-29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17505980
External Links:
ATC Codes:
AHFS Codes:
MSDS: Download
General Reference: # Todo T: Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci. 2008 Jan 1;13:2060-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17981691 # Radbill AE, Reddy AT, Markert JM, Wyss JM, Pike MM, Akella NS, Bharara N, Gillespie GY: Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain. J Neurovirol. 2007 Apr;13(2):118-29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17505980
External Links:
| Resource | Link |
|---|
| Resource | Link |
|---|
ATC Codes:
- Not Available
AHFS Codes:
- Not Available
MSDS: Download